ArticleHIV medicine2026
Differences in HIV testing may determine the first pillar of the HIV care continuum in a cross-border setting.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionIn border regions like the EuRegio Meuse-Rhine (EMR), mobility does not stop at the border. HIV risk may therefore not only be determined by within-country factors but also by between-country differences. We explored between-country differences in HIV indicators in the EMR using two complementary data-driven approaches.
methodsFirst, we used 2019-2021 surveillance data from the German Robert Koch Institute, the Belgian Health Institute Sciensano and the Dutch HIV Monitoring Foundation to report on the EMR-specific 95-95-95 goals. Second, we used the cross-sectional EMIS-2017 survey, including (trans)men who have sex with men (MSM), to report on determinants of HIV testing in the EMR. We employed multilevel multinomial regression modelling to identify sociodemographic factors associated with recent (<1 year), non-recent (≥1 year) and never testing for HIV, with a random effect for between-country effects.
resultsBased on 2021 surveillance data, the estimated number of individuals with HIV is 24 895, with 2236 individuals undiagnosed (9%). Countries differ most on the first pillar of the 95-95-95 goals: 95-93-96 in the Dutch, 90-98-96 in the German and 96-94-97 in the Belgian EMR-region, respectively. In EMIS-2017, half of MSM (n = 1335/2669) tested recently, 26% tested not-recently (n = 693) and 24% (n = 641) never tested for HIV; with 8% of HIV-testing variance explained by between-country differences. Non-recent and never-testing were both associated with socio-demographic factors, suggesting that some key populations (e.g., with transgender identity) and lack of resources determined differences in HIV testing.
conclusionTargeted approaches to address regional and socio-demographic differences are urgently needed, especially to tackle HIV-testing barriers and reach individuals undiagnosed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.